| MOLECUL AR FE ATURE S OF N SCLC
Molecular features of NSCLC tumors may not only predict the prognosis and outcome the cancer but also serve as targets for therapies. The most frequent mutations in NSCLC occur in the TP53 gene, occurring in about 50% of NSCLC cases ( Table 1 ). 9 Mutations in EGFR, a tyrosine kinase receptor, account for 10%-35% of cases and can cause dysfunction of the AKT and MAPK signaling which enhances cell survival and stimulates proliferation. 10 The most common mutations of EGFR are in-frame deletions of exon 19, and the second most common EGFR mutation is single nucleotide substitutions L858R in exon 21. 11 The most common mutation detected after treatment with EGFR inhibitors is T790M in exon 20 which can confer drug resistance. 12 The third most frequent mutations occur in KRAS, accounting for 15%-25% of cases. 13 Usually mutations in KRAS and EGFR are mutually exclusive and nonoverlapping. Another common molecular feature of NSCLC is the presence of ALK fusion gene, which encodes a receptor tyrosine kinase not normally expressed in the lung. 13 At least nine different variants of fusion of ALK with an upstream partner EML4 have been identified causing constitutive activation of the kinase. 13 The HER2 protein, a HER family receptor tyrosine kinase, is overexpressed in 20% of all NSCLC and gene amplification occurs in 2%. 14, 15 These mutations commonly lead to constitutive activation of the HER2 signaling pathway. 16 Mutations in the main catalytic subunit, PIK3CA, of phosphatidylinositol 3-kinase occur in about F I G U R E 1 Lung cancer classifications and frequency of diagnosis. There are two main types of lung cancer: small-cell lung cancer and non-small cell lung cancer. Small-cell carcinoma occurs in the outer edges of the lungs and accounts for about 15% of all cases. Non-small cell lung cancer (NSCLC) makes up 85% of all lung cancer cases, and can be further classified into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma, the most common NSCLC subtype, occurs in the cells lining the alveoli, squamous cell carcinoma is generally found in the airways or bronchi, and large cell carcinoma is in the edges of the lungs 2% of NSCLC cases. 17 These tumors can activate the protein kinase B signaling pathway without growth factors. Protein kinase B is encoded by AKT1, which is mutated from a glutamate to a lysine at position 17 in 1% of NSCLC cases and causes PI3K-independent activation of protein kinase B. 18, 19 BRAF is a member of the RAF kinase family which confers signaling of the MAPK family from the RAS GTPases to control cell proliferation. 20 BRAF mutations are mostly found in adenocarcinomas and lead to higher kinase activity and constitutively active MAPK2 and MAPK3 21 . MAPK2 and MAPK3 are downstream of BRAF and three mutations in the non-kinase portion of these proteins have been found in cancer. 22 Amplification of the gene MET, which codes hepatocyte growth factor receptor (HGFR) causes resistance to EGFR tyrosine kinase inhibitors. 23 The molecular heterogeneity of NSCLC tumors increases the complexity of treatment for NSCLC patients.
| CURRENT TRE ATMENTS FOR N SCLC PATIENTS
Lung cancer that is diagnosed at the early stages is commonly treated with resection surgery or lobectomy, chemotherapy, and radiation. Surgery may range from removing an entire lung to removing part of a lobe, depending on the size and location of the tumors. Radiation, alone or concurrent with surgery or chemotherapy is also commonly utilized. External beam radiation therapy, the most widely used form of radiation for NSCLC, consists of administering 1.5 to 2.5 Gray to the lungs usually 5 days a week for 5-7 weeks, while stereotactic radiotherapy consists of a larger dose, around 22 Gray, in usually fewer than 5 doses. 24 Brachytherapy, or internal radiation therapy, involves the inserting a radioactive pellet in or near the tumor for a short amount of time or permanently. The radiation stays localized and gets weaker over time. Radiofrequency ablation uses radio waves emitted from a probe guided by a computed tomography scan.
Molecular medicine or pharmacotherapy spans from chemotherapy
to targeted therapy and the most recent immunotherapy, which utilize small-molecule and protein or antibody drugs ( Table 2) . Commonly used chemotherapies for the treatment of NSCLC include cisplatin, carboplatin, docetaxel, paclitaxel, pemetrexed, and vinorelbine that usually interfere with DNA synthesis or replication to achieve the inhibition of cancer cell proliferation and growth (Table 2 ). Nevertheless, chemotherapy may not be effective for all patients and many cancers will eventually become resistant to the drugs. Furthermore, chemotherapy kills cancer cells less specifically and could cause some side effects like pain, nausea, vomiting, blood disorders, and hair-loss.
Pharmacotherapy for NSCLC has been benefited greatly by the development of targeted and personalized medications, either small molecules or antibodies, which act more selectively on particular molecular targets including transmembrane and cell surface proteins or receptors (eg, EGFR, PD-1, PD-L1, etc) as well as signal proteins (eg, cytokines, VEGF) and cytoplasmic kinases (eg, MEK) ( Table 2 ). While all the therapies listed in Table 2 are approved in the United States, many are also approved in Europe and elsewhere. The response rate for most of the therapies is generally consistent across subtypes with higher rates for tumors with high mutational burden. The effectiveness of two antibody drugs, anti-VEGF bevacizumab and anti-VEGFR ramucirumab, is attributable to the inhibition of angiogenesis. 25 NSCLC patients with an overexpression of EGFR mRNA or increased copy number have a 70% or higher response rate to small-molecule EGFR inhibitors like gefitinib or EGFR antibodies like necitumumab. 26 Furthermore, some targeted therapies are approved for specific subsets of NSCLC patients.
Osimertinib is used to treat NSCLC patients with T790M mutations of EGFR. The EML4-ALK tumors are mostly responsive to small-molecule tyrosine inhibitors of ALK like crizotinib. Dabrafenib and trametinib, which target BRAF and MEK1/2, respectively, are prescribed for patients with BRAF V600E mutations. 27 Immunotherapies such as PD-1 and PD-L1 antibodies (eg, nivolumab and atezolizumab) are also effective for the treatment of some NSCLC patients regardless of the subtype. 28 While targeted and immunotherapies are generally less toxic and personalized for particular patients, some patients do exhibit primary or acquires resistance 29, 30 or show severe adverse effects such as diarrhea and pneumonitis. [31] [32] [33] In addition, targeted therapies have the greatest response rate for patients with the indicated mutation, therefore, due to the high heterogeneity of mutations within NSCLC, targeted therapies may not work in every patient. Large efforts are underway to advance the understanding of NSCLC biology and assess novel therapies.
| G ENOME-DERIVED MICRORNA S ARE DYS REG UL ATED IN N SCLC
As less than 5% of the human genome is processed to functional proteins in cells, the majority is transcribed into enormous numbers of functional noncoding RNAs. Among them, microRNAs (miRNAs or miRs) are a superfamily of short RNAs that act on corresponding transcripts via complementary binding to achieve mRNA degradation or translation inhibition 34 (Figure 2 ). The biogenesis of miRNAs starts with the transcription of miRNA-coding genes into primary ( Figure 2 ). The miRNA duplex is then unwound to offer two strands, among which the guide strand is preferably incorporated into the RNA-induced silencing complex (RISC) consisting of the Argonaute family of proteins while the passenger strand is readily degraded. 36, 37 The RISC proteins stabilize and aid the mature miRNA in binding to the 3'-untranslated region (3'UTR) of a target transcript to accomplish the regulation of target gene expression ( Figure 2 ).
Many miRNAs are involved in the control of target gene expression behind various cancer cellular processes (see the following section), exhibiting tumor suppressive or promotive activities.
Specifically, a miRNA that reduces the expression of tumor suppressors acts as a tumor promotor, and a miRNA that degrades oncogene transcripts functions as a tumor suppressor. Interestingly, some miRNAs are dysregulated in NSCLC (Table 3 ) that may be indicative of disease status or therapeutic outcome. With some exceptions, generally there is a decrease of tumor suppressive miRNAs (eg, miR-34a-5p and miR-124-3p) and increase of tumor promotive miRNAs (eg, miR-21-5p and miR-183-5p) in many human cancers including NSCLC (Table 3) , as compared to normal tissues; however, the magnitude of dysregulation varies by case. Dysregulation of miRNA expression may be caused by different mechanisms such as chromosomal deletion or methylation, or dysregulation of their transcription factors, enzymes, or binding proteins involved in miRNA biogenesis. Dicer, the RNase responsible for the processing of pre-miRNAs, is essential for mouse development and stem cell maintenance. 38 Dicer was reported to be downregulated in some lung cancer patients, leading to a global decrease in miRNAs and associated with poor prognosis, 39 and conditional deletion of Dicer led to increased lung tumorigenesis in mice. 40 Actually, the role of Dicer in cancer remains contradictive. 41 It has been suggested that a partial loss or downregulation of Dicer is oncogenic, while a complete loss is tumor protective. In addition to Dicer, the expression of some miR-NAs is also modulated by the tumor suppressive transcription factor p53. 42 During DNA damage, p53 associates with the Drosha/DGCR8 complex and facilitates processing of pri-miRNA to pre-miRNA. p53
is mutated and inactivated in many cancers, including lung, 43 F I G U R E 2 MicroRNAs are derived from the genome to control target gene expression through their actions on mRNAs. Transcribed from the genomic DNA by RNA polymerase as primary miRNA (pri-miRNA) and subsequently processed by the Drosha/DGCR8 complex to a shorter form within the nucleus, the resultant precursor miRNA (pre-miRNA) is transported into the cytoplasm by Ran-GTP-dependent Exportin-5 (XPO5) and further processed by Dicer and TRBP to miRNA duplex. Unwinding of the duplex offers two strands, among which the passenger strand is readily degraded while the mature miRNA, guided by argonaut-2 (AGO2), acts on target transcript through complementary binding and leads to mRNA degradation or translational inhibition restoration of tumor suppressive miRNAs and inhibition of tumor promotive miRNAs represent new anti-cancer strategies.
| MI CRORNA S ARE INVOLVED IN THE CONTROL OF MULTIPLE N SCLC CELLUL AR PRO CE SS E S

| Epithelial to Mesenchymal Transition
The epithelial to mesenchymal transition (EMT) is a process in which an epithelial-like cell loses its attachment to the basal membrane and assumes mesenchymal characteristics like greater motility and invasiveness. EMT allows for cancer cells to metastasize by migrating from the primary tumor through the blood stream and invading other organs. Comprehensive reviews of the process of EMT have recently been published. 44 as vimentin and N-cadherin. 45 The EMT phenotype is reduced in NSCLC by the action of miR-17-5p, 20a-5p, and 20b-5p that directly target TGFβR2, 46 miR-148a-3p and miR-101-3p that target ROCK1 and ROCK2 respectively, 47, 48 and miR-132-3p, miR-638-5p, and miR-338-5p which target transcription factors ZEB2, SOX2, and SOX4, respectively 49-51 ( Figure 3 ). Both miR-149-5p and miR-509-3p target the transcription factor FOXM1 to reduce invasion in H1299 cells as determined by Matrigel invasion assay. 52 In addition, miR-186-5p targets CDC42 leading to the inhibition of migration and related EMT processes. 53 Likewise, dysregulation of these miRNAs, as evident in NSCLC, leads to greater EMT and a more invasive, migratory, and potentially metastatic phenotype.
| Signal transduction in lung cancer survival and proliferation
Oncogenesis is driven by an over-expression or activation of growth signaling, such as growth factors, receptors, or downstream signaling molecules. Growth factor ligands bind to their corresponding receptors to relay a signal and induce proliferation. Cancer cells can hijack signaling by over-expressing or mutating growth factor receptors to increase proliferative signals and miRNAs target certain receptor to modulate signaling. [187] [188] [189] [190] [191] [192] let-7c-5p Decreased N/K-RAS, ABCC2, Bcl-XL, ITGB3, MAP4K3, HOXA1 [122, [193] [194] [195] [196] miR-101-3p Decreased ZEB1, ROCK2, MALAT-1, EZH2 [48, 180, [197] [198] [199] target epidermal growth factor (EGFR) (Figure 3 ), which is commonly overexpressed in NSCLC (Table 1) , to alter downstream signaling molecules such as AKT and ERK1/2 and decrease the growth phenotype. In addition, miR-139-5p, 58 miR-30a-5p, 59 miR-140-3p, 60 miR-320a-3p 61 and miR-195-5p 62 all target insulin-like growth factor 1 receptor (IGF1R), while miR-486-5p directly targets both IGF1R and its ligand insulin-like growth factor 1 (IGF1) 63 and miR-135a-5p targets only IGF1. 64 miRNA inhibition of the IGF pathway results in a lower proliferation as assayed by CCK-8 kit among others. 60 miR-152-3p targets fibroblast growth factor 2 (FGF2) 65 and miR-99b-5p 66 and miR-100-5p 67 target fibroblast growth factor receptor 3 (FGFR3). MET is a receptor for the hepatocyte growth factor (HGF) and is targeted by a number of miRNAs including miR-130a-3p, 68 miR-449a-5p 69 miR-34a-5p, 70 miR-200a-3p, 57 miR-206-3p, 71 miR-31-5p, 72 miR-139-5p, 73 miR-329-3p, 74 miR-27b-3p 75 to decrease growth and proliferation.
EGF, IGF, FGF, and HGF signaling results in activation of RAS or PI3K pathways and downstream growth signaling. A decrease in the miRNAs that target growth factors and their receptors, as well as downstream targets, as evident in NSCLC, results in an increase in growth signal transduction and an increase in cancer cell proliferation and growth.
| Angiogenesis
Angiogenesis is the process of building new blood vessels for nutrients and gas exchange which is essential for cancer cells to survive and proliferate. Dysregulation of miRNAs in cancer cells can lead to increased angiogenesis through multiple pathways, including vascular endothelial growth factor (VEGF) or placenta growth factor (PIGF) binding to VEGF receptor (VEGFR) or neuropilin (NRP). 76 During HUVECs recruitment as well as inhibition of intratumoral capillary tube formation in vivo. 82 In one study, coculture of NSCLC cell lines with vascular endothelial cells leads to higher levels of miR-494-3p
in the vascular endothelial cells, in addition, a miR-494 antagomir decreases tumor vascularization, suggesting that miRNAs may be transferred to vascular endothelial cells to control angiogenesis. 83 Such miRNAs are important in the control and development of vascularization which is critical for tumorigenesis and metastasis.
| Cell Cycle
The cell cycle is altered among almost all cancer cells to allow for uncontrolled growth. Cyclins and cyclin-dependent kinases (CDKs) are partly responsible for entry into the different cell cycle stages. Figure 4 and Table 3 ). Tumor suppressive miR-34a-5p directly targets CCND1 and CDK6, leading to the arrest of the cell cycle in G 1 phase. 89 Furthermore, miR-15a-5p and miR-16-5p, down-regulated in NSCLC, directly targets CCND1, CCND2, and CCNE1, and arrests the cell cycle in G 1 to G 0 in an Rb-dependent manner. 90 Combination of miR-34a-5p and miR-15a/16 produces synergism in G 1 cell cycle arrest in an Rb-dependent manner due to an increase in miRNAs targeting more cell cycle related mRNAs. 91 In addition, miR-30d-5p targets CCNE2, 92 miR-186-5p targets CCND1, CDK2, and CDK6, 93 and miR-129-5p targets CDK6 94 to arrest the cells in G 1 . Generally, cell cycle-regulating miRNAs exhibit tumor suppressive actions by targeting cell cycle promotive genes to induce a cancer cell cycle arrest. and miR-497-5p 103 (Figure 5 ). In addition, BCL2L2 and BCL6, also anti-apoptotic proteins, are directly targeted by miR-15a-5p and miR-187-3p, respectively, to enhance apoptosis. 104 
| Evading Apoptosis
| Metabolism
Some miRNAs can alter the metabolic potential of cancer cells. A higher metabolic rate may enhance the tumorigenesis and growth of NSCLC cells. miR-155-5p promotes aerobic glycolysis by indirectly upregulating HK2, as determined by a hexokinase colorimetric assay as well as glucose and L-lactate test kits. 111 The increase in glycolysis leads to greater degree of cell viability. miR-143-3p directly targets HK2, the first rate-limiting enzyme in glycolysis, to decrease glycolysis and proliferation as well as tumorigenesis in vivo. 112 
| MI CRORNA S AFFEC T THE S EN S ITIVIT Y OF N SCLC CELL S TO CURRENT THER APIE S
Dysregulation of miRNAs can confer the resistance to current therapies including chemotherapy and radiation therapy. For instance, upregulation of miR-21-5p leads to a reduction of apoptosis and decrease of sensitivity to two chemotherapeutics, docetaxel and cisplatin. 110 Induced by radiation, miR-155-5p does confer resistance to radiation therapy by indirectly increasing HK2 to promote aerobic glycolysis. 111 Furthermore, chronic treatment with EGFR inhibitor gefitinib reduces the expression of miR-155-5p and miR-200c-3p and may decrease the sensitivity to gefitinib. 118 Therefore, miRNA profiles from tissue or body fluids may also be used as predictive biomarkers for the sensitivity of NSCLC tumors to certain therapies and to determine optimal therapies for the treatment of NSCLC. As an example, miR-143-3p is downregulated in NSCLC and suppresses NSCLC cell proliferation, migration, and invasion by regulating EGFR expression. 119 NSCLC patients showing lower miR-143-3p levels and higher EGFR levels may benefit from anti-EGFR therapy like gefitinib.
PI3K or VEGF inhibitors may be beneficial for patients with decreased expression of miR-126-3p because dysregulation of miR-126-3p may lead to an increase in PI3K and VEGF-A. 77, 120 In addition, miRNAs can play an important role in drug uptake and efflux via direct targeting of drug transporters. For example, miR-31-5p is upregulated in cisplatin resistant cell lines and directly regulates the expression of ABCB9, a drug transporter, to confers cisplatin resistance. 121 Let-7c-5p modulates the expression of ABCC2 transporter to sensitize cisplatin resistant cells. 122 ABCC4 involved in the transport of many anti-cancer drugs such as methotrexate and topotecan and is directly targeted by miR-124-3p and miR-506-3p. 123 Excellent reviews on the potential of miRNAs as biomarkers in lung cancer have been recently published. 124 Understanding miRNA-controlled regulation may not only improve the understanding of multidrug resistance mechanisms but also offer clues to the development of new therapeutic strategies. 125,126
| MI CRORNA S IMPAC T THE TUMORI G ENE S IS OF N SCLC CELL S
To determine the effect of a miRNA on tumorigenesis, investigators transiently or stably express the target miRNA in a cell line both miRNAs having the greatest impact. 129 By contrast, transgenic KRAS mutant mice with conditionally global overexpression of miR-21-5p showed much greater tumor burden as well as lower survival rate, as compared to KRAS mutant mice without miR-21-5p overexpression. 130 After subcutaneous implantation, H460 cells overexpressing miR-205-5p grew faster and led to greater tumor volume and vascularization, as compared to control cells. 131 Compared to corresponding controls, overexpression of miR-31-5p in three different lung cancer cell lines, H1993, H1437, and H460, led to an increase in subcutaneous tumor volume. 132 The same study also demonstrated that transgenic mice with a doxycycline-inducible miR-31-5p expression in the lung exhibited greater levels of hyperplasia and adenomas. 132 In conclusion, ectopic or overexpression of certain functional miRNAs can largely influence the tumorigenesis of NSCLC cells, which may provide insights into development of new miRNA-based therapies.
| THER APEUTI C P OTENTIAL OF MI CRORNA S DEMON S TR ATED IN N SCLC ANIMAL MODEL S IN VIVO
Two miRNA-based therapeutic strategies have been established, aiming to restore tumor suppressive miRNAs and inhibit tumor promotive miRNAs, respectively. Many studies were thus conducted to define the effectiveness of specific miRNA therapeutics for the treatment of NSCLC in animal models in vivo ( Table 5 ). AntagomiRs were employed for the inhibition of tumor promotive miR-21-5p, miR-183-5p, and miR-206-3p and shown to inhibit subcutaneous A549 tumors. 82, 133, 134 Whereas, tumor suppressive miRNAs let-7b-5p or miR-34a-5p reduced KRAS-activated tumor burden in vivo. 135 Let-7c-5p and let-7a-5p were both shown to decrease the progression of NSCLC in vivo. 136 Synthetic miR-34a-5p injected either intratumorally or through the tail vein was effective in inhibiting the growth of subcutaneous xenograft NSCLC, 137 and it did not show major impact on the cytokine profiles or liver or kidney functions.
A specific type of chemical modification of miR-145-5p, namely locked nucleic acid, delivered with a polyurethane-short branchedpolyethylenimine, led to significant inhibition of tumor growth and the effects were enhanced by radiation and cisplatin therapy. 138 Orthotopic NSCLC tumor growth, metastasis, and vascularization were decreased in mice treated with miR-200a/b. 129 Sensitized tumor to irradiation [146] miR-34a-5p and let-7b-5p (synthetic) Kras/p53 mutant, Creadenoviral activated
NOV340 (liposomal nanoparticle)
Combination of miR-34a-5p and let-7c-5p reduced tumor burden, decreased proliferation, and increased survival with minimal cytokine induction [140] anti-miR-21-5p (synthetic)
Subcutaneous A549 cell line
QTsome (cationic lipids) Stable tumor growth or tumor regression after treatment, increased survival [133] anti-miR-183-5p (synthetic) Subcutaneous A549-LUC-GFP
Adenovirus (intra-tumoral injection)
Decreased tumor growth as measured by luminescence [134] miR-206-3p-agomir (synthetic)
Subcutaneous A549 cell line
No vehicle mentioned (intra-tumoral injection)
Decreased tumor volume and formation of intra-tumoral capillary tubes, and increased apoptosis [82] experienced immune-related adverse effects where multiple deaths also occurred with complex and uncertain causes. The most common adverse effects were fever, fatigue, nausea, diarrhea, and vomiting, and laboratory abnormalities included lymphopenia, neutropenia, and increased AST among others. The study does not distinguish whether the toxicity resulted from the RNA or the liposomal carrier, however, both components have shown immune toxicities in previous studies. 148, 149 The immune-related toxicity suggests that more studies are warranted to understand the effect of miRNA therapies and the carriers on the immune system. The termination of this trial reiterates the importance of safety study in addition to efficacy during drug development. still of concern since RNA molecules are generally susceptible to serum RNases and cannot pass freely through cell membrane barriers. Chemical modifications and formulation with biocompatible lipids or polymers have proven useful for improving the metabolic stability and delivery of RNA therapeutics. As chemical modifications undoubtedly lead to different RNA folding, stability, biologic activity, and safety profiles, there are growing interests in producing biologic or recombinant RNA molecules in living cells for RNA research and drug development, 141, 142 similar as the success of protein-based therapeutic modalities. Improved formulations with lipid or polymer-based drug delivery systems may aid in protecting the RNA from degradation or recognition by the immune system. In any case, evidence is required to address two fundamental questions: whether the drug is effective against the disease and whether the drug is safe for the patients, which warrants more extensive studies. 
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